Similar Articles
1351 Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells
1352 Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression
1353 Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma
1354 Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis
1355 Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma
1356 Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications
1357 Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis
1358 A polymorphism within ErbB4 is associated with risk for hepatocellular carcinoma in Chinese population
1359 Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells
1360 Hepatocellular carcinoma in cirrhotic patients with portal hypertension: Is liver resection always contraindicated?
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA